Results 31 to 40 of about 1,288 (185)

A review of the fernane-type triterpenoids as anti-fungal drugs [PDF]

Frontiers in Pharmacology
Human fungal pathogens could cause a broad plethora of infections in both the immunocompetent and immunocompromised host. Fungal infections have become important causes of morbidity and mortality in recent years, the current arsenal of anti-fungal ...
Chun-Yue Liu, Chun-Yue Liu, Lu Zhang, Si-Xuan Liu, Yong-Fu Lu, Chang Li, Yue-Hu Pei   +6 more
doaj   +2 more sources

Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents [PDF]

Journal of Fungi
Vulvovaginal candidiasis (VVC) represents a widespread gynaecological challenge, affecting approximately 75% of women at some point during their reproductive years, with a significant subset progressing to recurrent forms (RVVC).
Guillermo Quindós, Iker De-la-Pinta, Cristina Marcos-Arias, Nerea Jauregizar, Elena Sevillano, Lucila Madariaga, Elena Eraso   +6 more
doaj   +2 more sources

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303) [PDF]

Clinical Infectious Diseases, 2021
Background Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity.
J. Schwebke, Ryan H. Sobel, J. Gersten, S. Sussman, S. Lederman, M. Amanda Jacobs, B. Chappell, D. Weinstein, A. Moffett, N. Azie, D. Angulo, I. A. Harriott, K. Borroto-Esoda, M. Ghannoum, P. Nyirjesy, J. Sobel   +15 more
semanticscholar   +3 more sources

Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study. [PDF]

Infection
To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC). A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC ...
Wang X, Wang W, Li J, An R, Chen L, Lin J, Xu D, Qiu J, Song W, Patiman M, Ruan H, Wang G, Xue F, Wang X, Luo X, Ruan Q, Shi L, Zhang C, Hu L, Wang S, Shi H, Wang X, Zhang S, Li Y, Lu J, Wang B, Xu H, Ye H, Zhang B, Zhang C, Qian S, Wu Q, Jia W, Li C, Liao Q.   +34 more
europepmc   +2 more sources

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis [PDF]

Clinical Infectious Diseases, 2021
Background Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles.
P. Nyirjesy, J. Schwebke, D. Angulo, I. A. Harriott, N. Azie, J. Sobel   +5 more
semanticscholar   +3 more sources

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306

Journal of Women's Health, 2022
Background: Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ...
O. Goje, Ryan H. Sobel, P. Nyirjesy, S. Goldstein, M. Spitzer, B. Faught, Shelagh B. Larson, Thomas King, N. Azie, D. Angulo, J. Sobel   +10 more
semanticscholar   +3 more sources

Ibrexafungerp: a novel oral triterpenoid antifungal, as an emerging therapeutic option in Vulvovaginal Candidiasis (VVC) [PDF]

Infectious Diseases and Tropical Medicine, 2022
OBJECTIVE: Vulvovaginal candidiasis (VVC) is a major concern for women of reproductive age group affecting more than 70% of total population of the mentioned population.
D. Chakraborty, S. Choudhury, S. Lahiry
doaj   +2 more sources

Draft genome sequence and annotation of the enfumafungin producing fungus Hormonema carpetanum ATCC 74360 [PDF]

BMC Genomic Data
Objectives Plant endophytic fungusHormonema carpetanum is the only organism known to produce enfumafungin to date. Enfumafungin is a fernane-type triterpenoid glycoside compound with broad-spectrum antifungal activity, and this leading compound has been ...
Haodong Chen, Junyi Wang, Songbai Yang, Jiawei Tang, Wen Tang, Shaoxin Chen   +5 more
doaj   +2 more sources

In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains

Antimicrobial Agents and Chemotherapy
Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti-Candida activity.
A. Aldejohann, Carolina Menner, N. Thielemann, Ronny Martin, G. Walther, O. Kurzai   +5 more
semanticscholar   +3 more sources

Engineered Fusion Enzyme‐Mediated Non‐Consecutive Cyclization‐Glycosylation Enables Heterologous Synthesis of Antifungal Enfumafungin

Advanced Science
Enfumafungin‐type antibiotics, represented by enfumafungin and fuscoatroside, constitute a distinct class of fungi‐derived fernane‐type triterpenoids renowned for their potent antifungal activity.
Yaohui Gao, Jianming Lv, Yue Zhong, Zhiqin Cao, Rui Luo, Yue Qi, Gaoqian Wang, Shaoyang Li, Guodong Chen, Dan Hu, Hao Gao, Xinsheng Yao   +11 more
doaj   +2 more sources